X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare J.B.Chemicals with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

J.B.CHEMICALS vs CIPLA - Comparison Results

J.B.CHEMICALS    Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    J.B.CHEMICALS CIPLA J.B.CHEMICALS/
CIPLA
 
P/E (TTM) x 17.0 34.0 50.0% View Chart
P/BV x 2.3 3.0 77.8% View Chart
Dividend Yield % 0.2 0.6 29.4%  

Financials

 J.B.CHEMICALS   CIPLA
EQUITY SHARE DATA
    J.B.CHEMICALS
Mar-16
CIPLA
Mar-18
J.B.CHEMICALS/
CIPLA
5-Yr Chart
Click to enlarge
High Rs318663 48.0%   
Low Rs200479 41.6%   
Sales per share (Unadj.) Rs148.0189.0 78.3%  
Earnings per share (Unadj.) Rs19.117.6 108.5%  
Cash flow per share (Unadj.) Rs23.934.0 70.4%  
Dividends per share (Unadj.) Rs0.503.00 16.7%  
Dividend yield (eoy) %0.20.5 36.8%  
Book value per share (Unadj.) Rs128.9176.7 73.0%  
Shares outstanding (eoy) m84.82805.12 10.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.73.0 57.9%   
Avg P/E ratio x13.632.5 41.8%  
P/CF ratio (eoy) x10.816.8 64.4%  
Price / Book Value ratio x2.03.2 62.1%  
Dividend payout %2.617.1 15.4%   
Avg Mkt Cap Rs m21,951459,724 4.8%   
No. of employees `0002.723.6 11.6%   
Total wages/salary Rs m1,84126,901 6.8%   
Avg. sales/employee Rs Th4,590.96,446.1 71.2%   
Avg. wages/employee Rs Th673.41,139.4 59.1%   
Avg. net profit/employee Rs Th592.1600.0 98.7%   
INCOME DATA
Net Sales Rs m12,551152,193 8.2%  
Other income Rs m5423,577 15.1%   
Total revenues Rs m13,093155,769 8.4%   
Gross profit Rs m2,05528,264 7.3%  
Depreciation Rs m41213,228 3.1%   
Interest Rs m961,142 8.4%   
Profit before tax Rs m2,08817,470 12.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-28 0.0%   
Extraordinary Inc (Exp) Rs m0-775 0.0%   
Tax Rs m4692,501 18.8%   
Profit after tax Rs m1,61914,166 11.4%  
Gross profit margin %16.418.6 88.1%  
Effective tax rate %22.514.3 156.9%   
Net profit margin %12.99.3 138.6%  
BALANCE SHEET DATA
Current assets Rs m7,778108,141 7.2%   
Current liabilities Rs m4,35838,322 11.4%   
Net working cap to sales %27.245.9 59.4%  
Current ratio x1.82.8 63.2%  
Inventory Days Days5597 56.4%  
Debtors Days Days8074 107.6%  
Net fixed assets Rs m5,713109,411 5.2%   
Share capital Rs m1701,610 10.5%   
"Free" reserves Rs m10,547140,682 7.5%   
Net worth Rs m10,937142,292 7.7%   
Long term debt Rs m036,621 0.0%   
Total assets Rs m15,574228,606 6.8%  
Interest coverage x22.816.3 140.1%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.80.7 121.1%   
Return on assets %11.06.7 164.4%  
Return on equity %14.810.0 148.7%  
Return on capital %20.010.0 200.6%  
Exports to sales %48.732.8 148.6%   
Imports to sales %7.10-   
Exports (fob) Rs m6,11549,883 12.3%   
Imports (cif) Rs m889NA-   
Fx inflow Rs m6,16951,691 11.9%   
Fx outflow Rs m1,28521,033 6.1%   
Net fx Rs m4,88430,658 15.9%   
CASH FLOW
From Operations Rs m1,39714,628 9.5%  
From Investments Rs m-320-8,540 3.8%  
From Financial Activity Rs m-1,196-3,855 31.0%  
Net Cashflow Rs m-1022,431 -4.2%  

Share Holding

Indian Promoters % 55.4 16.0 346.3%  
Foreign collaborators % 0.3 20.8 1.4%  
Indian inst/Mut Fund % 3.4 12.2 27.8%  
FIIs % 3.9 23.7 16.5%  
ADR/GDR % 0.0 1.1 -  
Free float % 37.0 26.2 141.2%  
Shareholders   30,437 161,166 18.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare J.B.CHEMICALS With:   GSK PHARMA  JUBILANT LIFE SCIENCES  DISHMAN PHARMA  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare J.B.CHEMICALS With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 307 Points Higher; Metal and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets traded on a positive note throughout the day and ended on a strong note. Gains were seen in the metal sector.

Related Views on News

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

J.B.CHEMICALS SHARE PRICE


Dec 17, 2018 (Close)

TRACK J.B.CHEMICALS

  • Track your investment in J.B.CHEMICALS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

J.B.CHEMICALS 8-QTR ANALYSIS

COMPARE J.B.CHEMICALS WITH

MARKET STATS